Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

Share Price is delayed by 15 minutes
Get Live Data
50.55    0.00 (0.00%)
Bid:
49.60
Ask:
51.50
Spread: 1.90 (3.831%)
Market Cap: £193.32m
BSC Live PriceLast checked at - London Stock Exchange

Intraday Br.small Co.2 Share Chart

Interim Management Statement

24 Oct 2011 07:00

RNS Number : 6568Q
British Smaller Companies VCT2 Plc
24 October 2011
 



 

British Smaller Companies VCT2 plc ("the Company")

 

Interim Management Statement

For the quarter ended 30 September 2011

 

British Smaller Companies VCT2 plc presents its interim management statement for the quarter ended 30 September 2011. This constitutes the Company's second interim management statement for the financial year ending 31 December 2011, as required by Rule 4.3 of the Disclosure and Transparency Rules. A copy of this interim management statement can be found at www.yfmep.com.

 

The total return at 30 September 2011, calculated by reference to the net asset value per Ordinary share and the cumulative dividends paid and proposed, is 96.6 pence per Ordinary share. This represents an increase of 0.6 pence per Ordinary share in the quarter, which is substantially a result from an overall increase in the value of the investment portfolio. In the nine month period to 30 September the overall increase in the value of the investment portfolio is 3.3 pence per Ordinary share (8.0%).

 

The unaudited net asset value per Ordinary share as at 30 September 2011 was 66.6p (30 June 2011: 68.0p).The movement represented a 0.6 pence per share increase in the investment portfolio and recognised the payment of a dividend of 2.0 pence per Ordinary share.

 

The number of Ordinary shares in issue at 30 September 2011 was 23,415,094 (30 June 2011: 23,359,278). In addition at 30 September 2011 the Company held 844,830 Ordinary shares in Treasury (30 June 2011: 757,380).

 

During the quarter the Company:-

- allotted 137,931 Ordinary shares of 10 pence each at a price of 72.5 pence per share, for total proceeds of £100,000;

- allotted 5,335 Ordinary shares of 10 pence each at a price of 62.7 pence per share, pursuant to its dividend reinvestment scheme; and

- re-purchased 87,450 Ordinary shares of 10 pence each at a price of 56.0 pence per share. These shares were placed in Treasury.

 

Net assets at 30 September 2011 comprised the following:

£000

% of net assets

Unquoted investments at fair value

7,200

46.2

Quoted investments at bid price

2,148

13.8

Gilt investments

2,099

13.5

Total investments

11,447

73.5

Cash and cash equivalents

4,042

25.9

Other net current assets (liabilities)

100

0.6

Net assets

15,589

100.0

 

The ten largest investments by valuation at 30 September 2011 were as follows:

 

£000

% of net assets

Digital Healthcare Limited

1,128

7.2

Deep-Secure Limited

1,040

6.7

Primal Pictures Limited

1,005

6.4

Immunobiology Limited

1,002

6.4

Waterfall Services Limited

700

4.5

Bluebell Telecom Group Limited

500

3.2

Bagel Nash Limited

400

2.6

Sirigen Limited

400

2.6

Harvey Jones Limited

352

2.3

Brady plc

283

1.8

Top ten investments

6,810

43.7

Other investments

2,538

16.3

Gilt investments

2,099

13.4

Total investments

11,447

73.4

 

 

During the three months ended 30 September 2011 the Company invested £400,000 into Bagel Nash, a bakery and established retail brand in the north east of England. A follow-on investment of £233,334 was also made to acquire further stock in Waterfall Services Limited, a provider of catering services to the education and care home sector.

 

Further cash proceeds of £275,000 have been received in the 3 months to 30 September 2011 relating to the Company's sale of DxS to Qiagen in 2009, representing a profit of £57,000 over the 30 June 2011 valuation.

 

Performance

This quarter has seen a significant fall in values across the quoted markets which has inevitably impacted portfolio valuations. However your Company's portfolio valuation has stood up well, showing an increase overall of 0.6p per Ordinary share as several businesses recorded positive results. The total return, calculated by reference to the net asset value plus cumulative dividends paid and proposed has increased by 0.6 pence to 96.6 pence per Ordinary share, with the cumulative dividend now representing 30.0 pence per Ordinary share.

 

 

Share Buyback Policy

 

The necessary authority to renew the share buyback policy was obtained at the General Meeting on 30 August 2011.

 

Outlook

In spite of the ongoing economic uncertainty in the markets significant progress continues to be made across the portfolio. There is also evidence of increasing new investment opportunities as businesses take advantage of changing market conditions and vendors look for equity solutions. Your Board believes this will translate into increasing investment opportunities over both the short and medium term. To take full advantage of this market opportunity the Board is seeking to increase the investment capacity of the Company over the coming months via an offer to raise up to £10 million.

 

 

20 October 2011

 

For further information please contact:

 

David Hall YFM Private Equity Limited Tel: 0113 294 5039

Jeff Keating Singer Capital Markets Limited Tel: 0203 205 7500

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSDMMZGKMZGMZM
Date   Source Headline
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:22 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:40 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
23rd Mar 202311:30 amRNSPublication of Circular
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNSAnnual Financial Report
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:50 amRNSTransaction in Own Shares
6th Dec 20229:58 amRNSOffer Update
6th Dec 20229:58 amRNSOffer Update
30th Nov 202212:30 pmRNSPublication of a Prospectus
30th Nov 202212:30 pmRNSPublication of a Prospectus
25th Nov 20229:30 amRNS3rd Quarter Results
4th Nov 20228:30 amRNSDividend Declaration
24th Oct 20229:00 amRNSChange of Registrar
3rd Oct 20221:30 pmRNSOffer Update
3rd Oct 20221:30 pmRNSOffer Update
3rd Oct 202212:24 pmRNSPayment of Dividend and Issue of Equity
28th Sep 202211:12 amRNSTransaction in Own Shares
20th Sep 20229:30 amRNSHalf-year Report
4th Aug 202211:45 amRNSDividend Declaration
2nd Aug 20221:15 pmRNSStatement re intention to fundraise
2nd Aug 20221:15 pmRNSStatement re intention to fundraise
29th Jun 202210:00 amRNSPurchase of Own Securities and Net Asset Value
21st Jun 20223:00 pmRNSInterim Management Statement
13th Jun 20223:51 pmRNSResult of AGM
6th May 20229:14 amRNSPayment of dividend and Issue of Equity
30th Mar 20228:00 amRNSTransaction in Own Shares
21st Mar 20221:15 pmRNSAnnual Financial Report
25th Feb 202212:03 pmRNSResult of General Meeting
31st Jan 202212:00 pmRNSPublication of Circular
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSIssue of Equity and Close of Offers
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
16th Dec 20219:57 amRNSTransaction in Own Shares
6th Dec 202110:37 amRNSPublication of Supplementary Prospectus
6th Dec 202110:33 amRNSPublication of Supplementary Prospectus
18th Nov 20218:08 amRNSInterim Management Statement
16th Nov 202110:06 amRNSPayment of dividend and allotment of shares
12th Nov 20217:00 amRNSClose of Offers to New Applications
12th Nov 20217:00 amRNSClose of Offers to New Applications
25th Oct 202112:08 pmRNSPayment of Dividend and Issue of Equity
19th Oct 202110:14 amRNSNet Asset Value and Dividend Re-investment Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.